Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00779467 · ClinicalTrials.gov registry record · Phase 1

Epidural Neostigmine for Labor Pain

A Phase 1 study of Labor Pain, sponsored by Wake Forest University.

Completed
Registry status
Phase 1
Development phase
200
Enrollment target
1
Study location

NCT00779467 is a Phase 1 study of Labor Pain that has completed, run by Wake Forest University. The registered enrollment target is 200 participants, roughly in line with the 190-participant average among 14 other Labor Pain trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00779467, a Phase 1 study of Labor Pain, has completed, sponsored by Wake Forest University.

COMPLETED
Registry status
Phase 1
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to see which dose of epidural neostigmine is the best additive to use with the numbing medication used in an epidural during labor.

Conditions Studied

Labor Pain

Interventions

  • DRUG Bupivacaine
  • DRUG Neostigmine
  • DRUG fentanyl

Study Locations (1)

North Carolina

  • Forsyth Medical Center - Winston-Salem

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2008-10
Est. Completion 2013-11
Phase Phase 1

Sponsor

Wake Forest University

100 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00779467

The ClinicalTrials.gov registry entry for NCT00779467 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 190-participant average among 14 other Labor Pain trials with a reported enrollment target. The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Labor Pain appearing as the primary indexed condition, and to 3 interventions - of which Bupivacaine is the first listed.

NCT00779467 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT00779467 about?

NCT00779467 is a clinical study titled "Epidural Neostigmine for Labor Pain". The purpose of this study is to see which dose of epidural neostigmine is the best additive to use with the numbing medication used in an epidural during labor.

What is the current status of trial NCT00779467?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2008-10. Estimated completion is 2013-11.

What conditions does trial NCT00779467 study?

This clinical trial studies the following conditions: Labor Pain.

What interventions are being tested in trial NCT00779467?

The interventions under investigation include: Bupivacaine (DRUG), Neostigmine (DRUG), fentanyl (DRUG).

Who is sponsoring clinical trial NCT00779467?

This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00779467 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Labor Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Labor Pain

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.